Xingqi Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for the SQ-23082 eye drops issued by the State Drug Administration, and approved to carry out clinical trials. This drug is an improved chemical class 2.1 drug. It is intended to be used to treat itchy eyes associated with allergic conjunctivitis. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.